Cargando…
Clinical and analytical validation of FoundationOne(®)CDx, a comprehensive genomic profiling assay for solid tumors
FoundationOne(®)CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing...
Autores principales: | Milbury, Coren A., Creeden, James, Yip, Wai-Ki, Smith, David L., Pattani, Varun, Maxwell, Kristi, Sawchyn, Bethany, Gjoerup, Ole, Meng, Wei, Skoletsky, Joel, Concepcion, Alvin D., Tang, Yanhua, Bai, Xiaobo, Dewal, Ninad, Ma, Pei, Bailey, Shannon T., Thornton, James, Pavlick, Dean C., Frampton, Garrett M., Lieber, Daniel, White, Jared, Burns, Christine, Vietz, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926248/ https://www.ncbi.nlm.nih.gov/pubmed/35294956 http://dx.doi.org/10.1371/journal.pone.0264138 |
Ejemplares similares
-
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin
por: Woodhouse, Ryan, et al.
Publicado: (2020) -
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021) -
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas
por: Sharaf, Radwa, et al.
Publicado: (2021) -
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision‐Making for Patients with Advanced Solid Tumors
por: Takeda, Masayuki, et al.
Publicado: (2021) -
PEDT-02 Clinical usage of NCC Oncopanel/FoundationOne CDx for pediatric/AYA patients with recurrent malignant brain tumors
por: Shibahara, Ichiyo, et al.
Publicado: (2020)